Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Bizzarri, IT

Cinzia Bizzarri, L'Aquila IT

Patent application numberDescriptionPublished
20090093530(2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them - The present invention relates to novel (2R)-2-phenylpropanamides bearing a 4-sulfonylamino substituent on the 4 position of the phenyl group and to pharmaceutical compositions containing them, which are used as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells, and which are useful in the treatment of various ELR+CXC chemokine-mediated disorders. In particular, the compounds of the invention are useful in the treatment and control of specific CXCR2 dependent pathologies such as BOS, COPD, angiogenesis and melanoma.04-09-2009
20090131441Metabolites Of 2-Arylpropionic Acid Derivatives And Pharmaceutical Compositions Containing Them - Metabolites of 2-(R)-4-isobutylarylpropionamides and pharmaceutical compositions containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these metabolites are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.05-21-2009
20090203652CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES - The compounds of formula (I):08-13-2009
20100152256(2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them - The present invention relates to novel (2R)-2-phenylpropanamides bearing a 4-sulfonylamino substituent on the 4 position of the phenyl group and to pharmaceutical compositions containing them, which are used as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells, and which are useful in the treatment of various ELR+CXC chemokine-mediated disorders. In particular, the compounds of the invention are useful in the treatment and control of specific CXCR2 dependent pathologies such as BOS, COPD, angiogenesis and melanoma.06-17-2010
201002677262-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.10-21-2010

Patent applications by Cinzia Bizzarri, L'Aquila IT

Cinzia Bizzarri, L' Aquila IT

Patent application numberDescriptionPublished
200803122932-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them - The present invention relates to selected (R)-2-phenyl-propionamides and (R)-2-phenyl-sulfonamides with a hydrogen bond acceptor atom/group in a well defined position in the chemical space. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.12-18-2008

Simone Bizzarri, Torino IT

Patent application numberDescriptionPublished
20080214186System for Monitoring the Quality of Service in a Communication Network - Monitoring system includes a set of peripheral monitoring agents including processing functionalities housed in SIMS. Such processing functionalities, depending at least on operating conditions of each terminal and its respective SIMS, are able to adaptively establish a distribution of measuring functionalities included in the peripheral monitoring agents between the terminal itself (for example storing them in the related memory or multimedia card) and its respective SIM.09-04-2008
20080311901Method and Apparatus for Evaluating the Performance of a Radiomobile Transmission System - A method for evaluating the performance of a radiomobile system including a core network, includes the steps of generating a signal through a first device and transmitting the signal to a second device through the core network, wherein the transmission step includes emulating a radio access network interposed between the first device and the core network.12-18-2008